A prospective clinical study for recombinant human interferon alpha 1b spray in the prevention of novel coronavirus (COVID-19) infection in highly exposed medical staffs.

A study on the efficacy and safety of recombinant human interferon alpha 1b spray in preventing novel coronavirus (COVID-19) infection in highly exposed medical staffs.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000030013

Enrollment

Unknown

Registered

2020-02-19

Start date

2020-02-20

Completion date

Unknown

Last updated

2020-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Experimental group:recombinant human interferon a1b spray

Control group:Blank

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 70 years old; 2. Non-suspected and non-confirmed cases; 3. Front-line medical staffs in designated hospitals during the outbreak of pneumonia caused by COVID-19; 4. Participate voluntarily and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Suspected cases and confirmed cases; 2. Patients with severe heart, brain, liver, kidney and other visceral diseases or other serious metabolic disorders and tumors; 3. People who could not complete the study for other reasons; 4. Pregnant or lactating women.

Design outcomes

Primary

Measure	Time frame
Blood routine examination;Chest CT;Arterial Blood Oxygen Saturation;	—

Secondary

Measure	Time frame
Incidence of fever;Incidence of cough;Incidence of pneumonia in imaging;	—

Countries

China

Contacts

Public ContactFeng Cao

Chinese PLA General Hospital

fengcao8828@163.com+86 13911798280

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026